SEATTLE, WA – Alpine Immune Sciences, Inc. (NASDAQ:ALPN) reported a recent transaction involving James N. Topper, a member of the company's board of directors. Topper sold a total of 19 shares of the company's common stock, with the transaction valued at approximately $1,226. The shares were sold at a price of $64.57 each.
This transaction took place on April 25, 2024, and was disclosed in a filing with the Securities and Exchange Commission on April 29. Following the sale, Topper's direct and indirect holdings in the company amounted to a total of 2,829,347 shares of common stock.
In addition to the sale, the filing also disclosed that Topper, through Frazier Life Sciences VIII, L.P., exercised a warrant to purchase 1,200,000 shares of Alpine Immune Sciences' common stock. The exercise price for this transaction was set at a nominal value of $0.001 per share, totaling $1,200 for the entire lot. The warrant was exercised on a cashless basis, which resulted in the company withholding 19 shares to cover the exercise price, with the remaining 1,199,981 shares issued to Frazier Life Sciences VIII, L.P.
The warrant, which had no expiration date and was immediately exercisable, has been fully exercised, and no shares remain following the transaction.
It is important for investors to note that the reported securities are held directly by Frazier Life Sciences VIII, L.P. James N. Topper, as one of the managing members of the general partner of Frazier Life Sciences VIII, L.P., disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest, if any.
This recent filing provides investors with insight into the trading activities of one of Alpine Immune Sciences' directors, offering a glimpse into insider transactions at the pharmaceutical preparations company.
InvestingPro Insights
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) continues to draw attention in the market, with a notable transaction from board member James N. Topper. While insider transactions like these are closely monitored, investors may also consider broader financial metrics and analyst insights to gauge the company's performance and outlook. According to InvestingPro data, Alpine Immune Sciences currently has a market capitalization of $4.24 billion USD, reflecting its standing in the pharmaceutical industry.
An analysis of Alpine Immune Sciences' recent financial performance shows a remarkable revenue growth of 95.84% over the last twelve months as of Q4 2023, with an even more impressive quarterly revenue growth of 1011.42% in Q4 2023. Despite these growth figures, the company has a negative gross profit margin of -37.41% for the same period, suggesting challenges in profitability and cost management.
InvestingPro Tips highlight that analysts have revised their earnings downwards for the upcoming period and anticipate a sales decline in the current year. This aligns with the company's current P/E ratio of -100.40, which suggests investor caution regarding future earnings potential. Moreover, the stock's RSI indicates it is in overbought territory, which could signal a potential pullback.
For those interested in a deeper dive into Alpine Immune Sciences' financial health and performance, InvestingPro offers additional tips, including insights on profitability, debt levels, and valuation multiples. There are currently 19 additional InvestingPro Tips available for ALPN, which can be accessed at https://www.investing.com/pro/ALPN. Investors looking to leverage these insights can use the coupon code PRONEWS24 to get an extra 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.